evrysdi
roche registration gmbh - risdiplam - vöðvaáfall, mænu - Önnur lyf við sjúkdómum í stoðkerfi - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
nexpovio
stemline therapeutics b.v. - selinexor - mergæxli - Æxlishemjandi lyf - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
metylfenidat actavis forðatafla 18 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 18 mg
methylphenidate stada hart hylki með breyttan losunarhraða 30 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
methylphenidate sandoz forðatafla 54 mg
sandoz a/s* - methylphenidatum hýdróklóríð - forðatafla - 54 mg
methylphenidate sandoz forðatafla 27 mg
sandoz a/s - methylphenidatum hýdróklóríð - forðatafla - 27 mg
methylphenidate stada hart hylki með breyttan losunarhraða 20 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð; methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg
medikinet cr (medikinet retard) hart hylki með breyttan losunarhraða 30 mg
medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
attentin tafla 10 mg
medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 10 mg
attentin tafla 20 mg
medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 20 mg